A Phase 1 Pharmacokinetic Study of Oral IXAZOMIB (MLN9708) Plus Lenalidomide and Dexamethasone in Asian Patients With Multiple Myeloma
Phase of Trial: Phase I
Latest Information Update: 21 Jul 2017
At a glance
- Drugs Ixazomib (Primary) ; Dexamethasone; Lenalidomide
- Indications Multiple myeloma
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Takeda Oncology
- 17 Jul 2017 Status changed from active, no longer recruiting to completed.
- 13 Mar 2017 Results (n=755) of pooled analysis of (C16001,C16002,C16003,C16004,C16005,C16007,C16008,C16010,C16013,TB-MC010034) ten studies assessing pharmacokinetic analysis of Ixazomib published in the Clinical Pharmacokinetics.
- 22 Nov 2016 Planned End Date changed from 1 Aug 2015 to 1 May 2022.